The pros and cons of building your own home

Around 13,000 houses a year are self-builds — but what does this actually involve?

Green Cross Corporation (006280.KS)

KSE - KSE Delayed price. Currency in KRW

Add to watchlist

221,500.00

+3,500.00

(+1.61%)

At close: 03:30PM KST

Loading interactive chart…

Business Wire
GC Pharma Announces EMA Grants Orphan Drug Designation to Hunterase ICV, The World’s First Enzyme Replacement Therapy for Mucopolysaccharidosis Type II Administered by ICV Injection
YONGIN, South Korea, November 01, 2021--GC Pharma (006280.KS) today announced that the European Medicines Agency (EMA) granted orphan drug designation (ODD) to Hunterase ICV (intracerebroventricular, generic name: idursulfase-beta (recombinant)) for the treatment of mucopolysaccharidosis type II (Hunter syndrome) in the European Union.
Business Wire
GC Pharma Reports Q3 2021 Results
YONGIN, South Korea, November 01, 2021--GC Pharma (formerly known as Green Cross Corporation) (KRX: 006280), a South Korean biopharmaceutical company, today announced unaudited consolidated financial results for the three months ended 1 November 2021.
Business Wire
GC Pharma Announces GreenGene F Approval in China for the Treatment of Haemophilia A
YONGIN, South Korea, August 12, 2021--GC Pharma (006280.KS) today announced the approval of GreenGene F (Beroctocog alfa) [Recombinant Human Coagulation Factor VIII for injection] for the control and prophylaxis of bleeding episodes in individuals with haemophilia A in China by the National Medical Products Administration (NMPA). GreenGene F was initially approved by the Korean health authority in 2010 for control and prevention of bleeding episodes in patients with haemophilia A.